US 12280093
Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy
granted A61KA61K38/179A61K47/65
Quick answer
US patent 12280093 (Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 33
- CPC classes
- A61K, A61K38/179, A61K47/65, A61K9/0019, A61P